MOLN Stock : Investors haven’t had much reason to celebrate over in 2022. Major market indexes are in decline. The same is true for stocks.
It’s difficult for any stock to generate positive returns when the market is down. However, it’s not impossible to achieve this. Below are three stocks that have been soaring when the market fell -and whether they’re worth investing in today.
Molecular Partners
Molecular Partners‘ ( MOLN 2.14 percent) shares have skyrocketed over 40% in the year to date. The biggest driver for the biotech company was the positive results from a Phase 2 study of COVID-19’s experimental therapy the drug ensovibep.
On January. 10th, Molecular Partners and Novartis have announced good results of their Empathy Phase 2 . The study involved ensovibep treating COVID-19 patients with acute COVID. Ensovibep was able to meet the primary goal of the study, which was decrease in the viral load over 8 days. It also met the study’s secondary goals of fewer hospitalizations and/or emergency room visits as well as death, and the time required to sustain recovery from clinical illness when compared with placebo.
These results were so remarkable that Novartis took advantage of its right to obtain ensovibep’s license by Molecular Partners. The two companies intend to pursue U.S. emergency Use Authorization (EUA) for the drug as well as authorizations for other countries, too.
Returns on Ag Investments of Molecular Partners against. S&P
| 1 YEAR | 5 YEAR | 5 YEAR ANNUALIZED | SINCE IPO | |
|---|---|---|---|---|
| MOLN | -74.53% | -66% | ||
| S&P | -9.18% | +56.15% | +9.31% | -3% |
Assets
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Net Cash | $271.41M | +64.1% |
| Accounts Receivable | $1.76M | -70.6% |
| Inventory | 0 | – |
Liabilities
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Long Term Debt | $4.02M | -27.2% |
| Short Term Debt | $1.22M | -4.4% |
Ratios
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Return On Assets | 53.9% | – |
| Return On Invested Capital | -47.0% | +22.1% |
Cash Flow
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Free Cash Flow | -$19.62M | -6.7% |
| Operating Free Cash Flow | -$19.43M | -5.8% |
Valuation
QUARTERLYANNUAL
| Q4 2021 | Q1 2022 | Q2 2022 | Q3 2022 | YOY CHANGE | |
|---|---|---|---|---|---|
| Price to Earnings | – | 5.76 | 1.71 | 1.69 | – |
| Price to Book | 4.64 | 5.64 | 0.76 | 0.78 | -82.0% |
| Price to Sales | 58.10 | 3.39 | 1.07 | 1.07 | – |
| Price to Tangible Book Value | 4.65 | 5.65 | 0.76 | 0.78 | -82.0% |
| Price to Free Cash Flow TTM | – | 6.06 | 1.87 | 1.83 | – |
| Enterprise Value to EBITDA | -29.20 | 2.12 | 12.12 | 3.33 | – |
| Free Cash Flow Yield | – | 16.5% | 53.4% | 54.7% | – |
| Return on Equity | – | 58.9% | 60.6% | 65.8% | – |
| Total Debt | $6.63M | $6.24M | $5.69M | $5.23M | -23.0% |
